Abstract
In 4 patients with chronic myelocytic leukemia, a solitary rise in serum S-ALP was noted 2-12 mo. prior to death. All patients had received busulfan (Myleran) therapy for longer than 12 mo. (total dosage 1.0-2.4 g). The increase in S-ALP apparently was due to a cholestatic liver damage, possibly secondary to the busulfan treatment.

This publication has 2 references indexed in Scilit: